AstraZeneca and Ionis's Wainua misses in Phase 3 heart trial CARDIO-TTRansform, likely due to overlap with Pfizer's Vyndamax; AZ weighs next steps.
ESC Congress in Munich (Elizabeth Cairns for Endpoints News)
August 28, 2026 05:10 AM EDT
R&DPharma
Future of AstraZeneca’s gene silencer in heart disease uncertain after trial failure
Elizabeth Cairns
ESC: AZ, Ionis' Wainua post-mortem throws water on silencer-plus-stabilizer approach in ATTR-CM
In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs
AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease
AstraZeneca and Ionis detail surprise failure of heart disease drug, with Alnylam closely watching
New data could widen use of AstraZeneca, Amgen immune disease drug
Alnylam's heart drug troubles take center stage at a cardiology conference
AstraZeneca shares sink up to 9% after Wainua misses cardiovascular endpoint in Phase 3 ATTR-CM trial with partner Ionis.
After a surprise washout in a recent phase 3 trial of AstraZeneca and Ionis’ antisense oligonucleotide Wainua (eplontersen), the…
UK pharmaceutical company said Wainua drug did not meet goal of reducing cardiovascular deaths
AstraZeneca shares fell after Wainua failed a key trial. The drug did not reduce cardiovascular deaths or heart problems. Wainua…
Drug developed with Ionis could not reduce cardiovascular deaths or recurring heart problems
AstraZeneca and Ionis reported a notable trial failure Thursday in a heart disease that's become an increasingly competitive…
